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Introduction
 
Renal cell carcinoma (RCC) is a common malignancy. In 
2012, in the USA, there were 65,000 new cases and 13,500 
disease-specific deaths. In the same year it was the 6th most 
common new cancer diagnosed (1). During the last 50 years, 
despite an increase in incidence, the mortality has fallen, 
a possible result of earlier detection and improvements in 
therapy (2).
Traditionally, renal cell cancer has proven refractory to 
cytotoxic therapies, and for many years immunotherapy was 
the standard of care, even though it was not particularly 
effective. Over the past decade, the molecular biology 
behind renal cancer development has been better 
understood and subsequently a number of targets have been 
identified for potential therapies (3). 
Mutations in the tumour suppressor Von Hippel-Landau 
(VHL) gene are responsible for the majority of cases of 
sporadic clear cell renal cell carcinoma. VHL mutations 
result in aberrant binding of hypoxia-inducible factor 1 
(HIF1) subunits which translocate to the cell nucleus and 
result in transcriptional activation of a number of factors 
necessary for angiogenesis, including the vascular endothelial 
growth factor (VEGF) (4). Efforts directed towards inhibiting 
neoplastic neoangiogenesis, via the VEGF or the mammalian 
target of rapamycin (mTOR) pathways (5), have yielded 
positive results with clinical benefit.
To date, four tyrosine kinase inhibitors (TKI’s) have 
been shown to benefit patients in phase III randomized 
c o n t r o l l e d  t r i a l s :  s u n i t i n i b  ( 6 ) ,  s o r a f e n i b  ( 7 ) , 
pazopanib (8) and axitinib (9). Similarly, randomized 
data has also supported the use of the mTOR inhibitors 
temsirolimus (10) and everolimus (11). Despite these 
encouraging data, improvements in progression free 
survival (PFS) and overall survival (OS) have been measured 
in months, and not all patients have benefited uniformly. 
Hence a need exists to develop robust biomarkers for renal 
cancer that will help direct therapy in patients destined to 
do either very well or poorly.
A biomarker is defined as a characteristic that is 
objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention (12). Biomarkers 
serve an important role in oncology. They can assist in 
diagnosis, screening, prognosticating and as measures of 
response to certain therapies (4,13). A prognostic biomarker 
is able to estimate the chance of disease recurrence or 
death, regardless of any intervention (14). Conversely, 
a predictive factor is one which assists in predicting the 
probability of a response to a certain therapy (4). Predictive 
markers can provide information about the effect of a 
particular treatment, or serve as a target of a particular 
intervention (14). Identifying predictive biomarkers can 
therefore identify patients most likely to benefit from 
certain treatments. This maximizes efficacy and minimizes 
unnecessary exposure of patients to toxic therapies for 
which they are destined to derive no benefit.
As the molecular understanding of the pathogenesis 
of renal cell carcinoma has grown, a number of potential 
predictive markers have become apparent. In this review, 
we describe the predictive factors related to each of the 
tyrosine kinase inhibitors that are presently available for the 
treatment of metastatic renal cell carcinoma. Due to space 
constraints, we will consider only molecular biomarkers.
Sunitinib
Sunitinib is an tyrosine kinase inhibitor targeting VEGF 
receptors-1, -2, -3, platelet-derived growth factors, KIT, 
FLT-3, colony-stimulating factor-1 receptor and RET (15). 
The pivotal phase III trial of treatment-naive patients 
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with metastatic RCC showed significant improvements in 
response rate, progression-free and overall survival (16) 
with similar results confirmed in an expanded-access trial of 
over 4,000 patients (17). However, not all patients respond 
to sunitinib and some develop significant toxicities resulting 
in dose delays, reductions or discontinuations. There is 
emerging evidence for the importance of maintaining 
suninitib exposure in maximising efficacy (18), and therefore 
potential biomarkers are needed to identify patients who 
will most likely benefit or develop significant toxicities.
Single nucleotide polymorphisms (SNPs) have been 
investigated as potential biomarkers, particularly in 
angiogenesis and drug metabolising genes such as CYP3A4. 
In a prospective pharmacogenomic study of 101 patients with 
advanced clear cell RCC, Garcia-Donas and colleagues (19) 
reported two VEGFR3 missense polymorphisms (rs307826 
and rs307821) that were associated with a reduced PFS 
with sunitinib use (HR 3.57 and 3.31 respectively). The 
authors also discovered that the CYP3A5*1 (rs776746) 
high metabolising allele was associated with increased 
dose reductions due to toxicity (HR 3.75). Several smaller 
studies have reported associations between genetic variants 
in VEGF and VEGFR2 (20), CYP3A5, NR113 and ABCB1 
genes (21) and outcomes. A large prospective multinational 
trial, of which 75% of the 219 enrolled patients had 
metastatic renal cell carcinoma, identified variants in 
CYP1A1, ABCB1, ABCG2, NR113, VEGFR2 and FLT3 
genes that were associated with toxicity from treatment 
with sunitinib (22). A retrospective study of 135 patients (65 
who received sunitinib) examined the associations between 
four molecular markers (HIF-1α, CAIX, PTEN and p21) 
determined by immunohistochemistry and outcomes from 
treatment. CAIX overexpression was associated with more 
responses to newer targeted agents (64.7% versus 21.1%). 
High PTEN and low P21 expression were associated with 
an improved response to sunitinib (23).
Several plasma markers have been investigated for 
their role in predicting clinical outcomes, including those 
involved in angiogenesis such as VEGF and VEGF-
related proteins, placental growth proteins, SDF-1, 
sVCAM-1 (24-28) and cytokines (29). Rini and colleagues 
[2008] reported the value of baseline sVEGFR-3 and 
VEGF-C as potential biomarkers of PFS and RR (28). 
Several small prospective studies have shown that sunitinib 
therapy leads to modulation of circulating proteins involved 
in VEGF signaling. In these studies, significant changes in 
VEGF, sVEGFR-2, sVEGF3, PDGF and SDF-1 between 
baseline and either day 14 or 28 led to associations with 
RR, PFS and OS (24,26). TNF-alpha and MMP-9 were 
identified as potential biomarkers of sunitinib activity in a 
study of 31 patients. Five candidate cytokines (TNF-alpha, 
MMP-9, ICAM-1, BDNF and SDF-1) were evaluated and 
elevated levels of TNF-alpha and MMP-9 were associated 
with reduced PFS and OS (29). 
Emerging evidence suggests that circulating endothelial 
cells (CECs) and circulating endothelial progenitor cells 
(CEPs) may be promising as potential biomarkers with 
sunitinib treatment. Several studies have examined the 
dynamics of CECs with sunitinib treatment, and suggested 
significant CEC increases during treatment represent 
the targeting of immature tumour vessels (30) and are 
associated with improved PFS (31). Conversely, Farace and 
colleagues [2011] found no association between baseline 
changes in CECs and PFS or OS (24). The role of CEPs 
are unclear, however studies have shown an increased 
recruitment of these cells and haematopoietic progenitor 
cells into the neoangiogenic perivasculature, playing an 
important role in events necessary for tumour invasion 
and metastasis (24). Although promising, the reliability 
and sensitivity of measurements of CECs and CEPs using 
flow cytometry remains an issue and may limit its use in the 
research setting and application in clinical practice.
Sorafenib
Sorafenib is a tyrosine kinase inhibitor targeting serine/
threonine kinase Raf-1 (Wilhelm et al., 2004) and VEGFR, 
platelet-derived growth factor receptor receptor β 
(PDGFR-β), c-KIT, RET, and FLT-3 (32,33). Sorafenib 
is able to directly affect tumor cell proliferation as well as 
angiogenesis (34).
A randomized Phase II study of sorafenib with or 
without interferon alfa-2b (35) showed no particular 
benefit of the combination, though it is likely the study 
was underpowered, as only 80 patients were randomized. 
Nevertheless, increased pAkt predicted for poorer 
progression-free survival and overall survival.
In the pivotal Phase III treatment approaches in renal 
cancer evaluation (TARGET) trial, 903 previously treated 
RCC patients were randomly assigned to sorafenib or 
placebo. In the final analysis reported by Escudier et al. (7), 
OS was not different between patients in the sorafenib 
or placebo arm, though when post cross-over effects 
were excluded, OS did continue to favour sorafenib (HR 
0.78, P=0.029). In that study, baseline VEGF levels were 
prognostic for both PFS and OS. In a further subset 
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biomarker analysis of that study, a number of biological 
markers were found to be prognostic for survival: VEGF, 
carbonic anhydrase IX (CAIX), tissue inhibitor of 
metalloproteinase 1 (TIMP-1), and Ras p21 levels. Of these, 
only TIMP-1 was found to be independently prognostic in 
multivariate models (36). However, VHL mutational status 
was not related to sorafenib benefit. 
Pazopanib
Pazopanib is an oral tyrosine kinase inhibitor that received 
FDA approval in 2009 for the treatment of metastatic renal 
cell carcinoma. It binds to VEGF receptor-1, -2 and -3, 
platelet derived growth factor (PDGF) receptor -α and -β 
and c-kit receptors (37). In a phase III study published in 
2010, 435 patients with metastatic renal cell carcinoma, half 
of who had previously received cytokine treatment, were 
randomised to placebo or pazopanib. The pazopanib arm 
was associated with a superior progression free survival (9.2 
vs. 4.2 months, P<0.0001) and a better overall response rate 
30% vs. 3% (P<0.0001) (8). 
Xu and colleagues (38) tested their hypothesis that 
genetic polymorphisms are associated with differing clinical 
responses to pazopanib. 27 polymorphisms, known to 
affect angiogenesis, metabolism or the mode of action of 
pazopanib were identified and retrospectively tested in 397 
patients previously enrolled in pazopanib vs. placebo clinical 
trials. Polymorphisms in interleukin 8 (IL-8) and HIF1A 
were associated with a significantly poorer progression free 
survival compared to the wild type form (27 vs. 48 weeks, 
P=0.01 and 20 vs. 44 weeks, P=0.03 respectively). Inferior 
response rates were noted in patients expressing variant 
HIFA, NR1I2 and all three subsets of the VEGF gene. 
Similar associations between PFS and variant IL-8 and 
HIF1A were not seen in those patients treated with placebo, 
and hence these polymorphisms were considered to be 
predictive biomarkers.
These findings have biological merit; IL-8 is up regulated 
in murine models exposed to another TKI, sunitinib, 
and provides an alternative pathway to angiogenesis and 
drug resistance (39). Variant forms of HIF1A are known 
to provide endothelial cells with a greater capacity for 
angiogenesis (40), and ability to overcome the antineoplastic 
activity of pazopanib.
Recently, Tran et al. (41) examined the predictive and 
prognostic utility of circulating cytokine and angiogenic 
factors (CAF’s) in patients with metastatic renal cell 
carcinoma treated with pazopanib. A small number of 
biomarkers were selected and then determined in stored 
serum from patients involved in the earlier pazopanib 
phase II and III clinical trials. Using a systematic process, 
these biomarkers were tested in the phase II study, and 
then validated in the larger phase III trial. Although 
high concentrations of IL-6, IL-8 and osteopontin were 
prognostic, only IL-6 demonstrated greater benefit relative to 
placebo. In the placebo arm, an elevated level of IL-6 above 
the median (relative to below the median) was associated with 
a statistically superior PFS of 9.9 vs. 24 months (P<0.0001). 
Although a difference also existed in the pazopanib group, 
it was no longer statistically significant (33 vs. 42 months, 
P=0.445). The authors concluded that high levels of 
IL-6 were predictive of PFS benefit with pazopanib. 
Similar results were not noted for overall survival, a likely 
consequence of the high level of cross over in the original 
phase III trial.
Aiming to validate these findings, Liu et al. (42) 
retrospectively re-tested a selection of biomarkers from 
patients in the original phase III trial and again found IL-6 
to be predictive of an improved PFS in patients treated 
with pazopanib. IL-6 has been described as an independent 
predictor of poorer survival in metastatic renal cancer 
as early as 2004 (43) and has also been implicated in the 
paraneoplastic manifestations of the disease, including fever, 
weight loss and anaemia (44).
In a retrospective study presented in an abstract form in 
2008, low levels of serumVEGF-2 correlated with response 
rate in patients with metastatic renal cancer treated with 
pazopanib (45). In a separate pre-clinical study, a nuclear 
medicine tracer linked the VEGF receptor was shown to 
provide evidence for early tumour regression in murine 
models treated with pazopanib (46). Such a tracer may 
allow for an immediate assessment of anti-tumour efficacy 
and provide much more timely information than standard 
radiological evaluation. The lack of a placebo control in 
these two studies make it difficult to conclude that these 
biomarkers are indeed predictive for outcome.
Temsirolimus and everolimus
The mammalian target of rapamycin (mTOR) pathway 
has become a successful target for two new FDA approved 
agents in renal cancer, Temsirolimus and Everolimus. Two 
Phase III trials have established a benefit of these agents 
either used first line in poor risk patients or following 
treatment with a tyrosine kinase inhibitor (10,47). 
The advanced renal cell carcinoma (ACRR) trial 
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randomized treatment-naïve patients to temsirolimus, 
interferon-α (IFN) or a combination. Patients receiving 
temsirolimus alone experienced a progression free survival 
and overall survival benefit compared to IFN-α or the 
combination arm (10). Tumour samples in this study were 
assessed using immunohistochemistry for a range of potential 
molecular markers including HIF1α, HIF2α, phosphorylated 
Akt (pAkt) and phosphatase and tensin homolog (PTEN). 
In the single treatment arms, data was assessed in only 50% 
of patients for HIF1α and PTEN and not at all for pAKT 
and HIF2α. Neither baseline PTEN nor HIF1α levels were 
found to be of predictive value (48). In an explanation for 
this, the authors cited a number of logistical issues (poor 
tissue availability and an inability of immunohistochemistry 
to detect subtle biomarker quantities), which made this type 
of analysis difficult to perform.
Cho et al. assessed baseline levels of carbonic anhydrase 
IX (CAIX), phosphorylated S6 (pS6), pAkt and PTEN in 
tumour specimens from 20 patients receiving temsirolimus 
in a phase II trial. Patients with increased expression of 
pS6 were more likely to have a clinical response. Although 
a similar trend was found for pAkt, this did not reach 
statistical significance (49). These biomarkers deserve 
further study to establish if they are of predictive value in 
patients receiving treatment with an mTOR inhibitor.
Lactate  dehydrogenase  (LDH) has  prognost ic 
significance in RCC. Elevated levels of LDH are associated 
with reduced OS, and as such are widely incorporated into 
prognostic models (50-52). Retrospective analysis of the 
ARCC trial found that pretreatment LDH levels (>1× upper 
limit of normal (ULN)) were associated with an adjusted 
hazard ratio (HR) for death of 2.81 (P<0.001). For patients 
with an elevated LDH (>1× ULN), OS was improved in the 
patients receiving temsirolimus compared to IFNα with a 
HR for death of 0.56 (P=0.002) with no difference found in 
patients with a low LDH (53) .
Axitinib
Axitinib is an oral tyrosine kinase inhibitor with activity 
against vascular endothelial growth factor receptors (VEGF) 
1, 2 and 3 (54). It binds with increased affinity to VEGF-2, 
thereby differentiating it from other TKI’s (55). In addition to 
activity in renal cell cancer, Axitinib has demonstrated 
efficacy in thyroid, breast, non-small-cell lung cancer 
cancer (56-58). The phase III AXIS trial randomized 723 
previously treated patients to either Axitinib or Sorafenib (9). 
Axitinib was associated with a PFS benefit of 6.7 vs. 4.7 months 
(P<0.0001) and was subsequently approved by the FDA in 
early 2012. The role of Axitinib as a second line therapeutic 
option however, is not clearly defined given the positive results 
of everolimus also in the second line setting (47). 
Given its relatively recent history, there are comparatively 
few published studies regarding predictive molecular 
biomarkers for axitinib. In a phase I study conducted by 
Mukohara et al. (59), 12 patients were administered Axitinib 
in escalating doses. Axitinib exposure correlated inversely 
with the concentration of soluble growth factor receptor 2 
(s-VEGFR2), This observation appeared to be a function 
of drug concentration and was not predictive of efficacy. 
The association between s-VEGF2 and Axitinib was further 
explored in a phase I study conducted by Tomita et al. (60). 
A PFS benefit existed for those patients with s-VEGF-2 
concentrations below the median (13 vs. 9 months, P=0.01). 
Although these results were interesting, this trial was not 
placebo controlled, and therefore could not conclusively 
prove that s-VEGF2 is a predictive marker. 
Conclusions
At the present time there is no prospectively validated 
predictive or prognostic biomarker to help guide treatment 
selection decisions for which patients might most benefit 
from therapy with one tyrosine kinase inhibitor over 
another. While there are several candidate markers that 
deserve further investigation, there needs to be an increased 
focus on incorporation of biomarker assessment into large 
prospective clinical trials if we are to understand the clinical 
significance of these biomarkers. Even so, the collection of 
biomarker samples based on convenience leads to difficulty 
in interpretation of results. Ideally, the best biomarkers 
should be defined upfront and clinical trials of therapy 
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